Bt Ashely Bebensee, Kearney Hub
A $70 million expansion project for Becton, Dickinson and Company largely will affect the company’s Holdrege facility.
BD announced in July a partnership with the federal Biomedical Advanced Research and Development Authority to manufacture injection devices necessary to support current and future pandemic vaccination efforts, according to a news release.
“All of the new syringe and needle lines will be installed at our facility in Holdrege. We will be adding some capacity in Columbus for cannula grinding (part of the process to manufacture needles), but the vast majority of the work will be in Holdrege,” said Troy Kirkpatrick, BD’s senior director of public relations, in an email.